Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Jas Bindra, Ishveen Chopra, Kyle Hayes, John Niewoehner, Mary Panaccio & George J Wan. (2023) Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis. ClinicoEconomics and Outcomes Research 15, pages 739-752.
Read now
Read now
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
Jas Bindra, Ishveen Chopra, John Niewoehner, Mary Panaccio & George J Wan. (2021) Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis. ClinicoEconomics and Outcomes Research 13, pages 349-358.
Read now
Read now
Carrie M. Hersh, Richard A. Brook, Ian A. Beren, Nicholas J. Rohrbacker, Lori Lebson, Christian Henke & Amy L. Phillips. (2021) The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis. Journal of Medical Economics 24:1, pages 479-486.
Read now
Read now
Emanuele D’Amico, Clara G Chisari, Lara Gitto, Aurora Zanghì, Simona Toscano & Francesco Patti. (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy 20:11, pages 1331-1340.
Read now
Read now
Ewa Stawowczyk, Krzysztof Piotr Malinowski, Paweł Kawalec & Paweł Moćko. (2015) The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 759-786.
Read now
Read now
Sander Yermakov, Matthew Davis, Michaela Calnan, Monica Fay, Brieana Cox-Buckley, Sujata Sarda, Mei Sheng Duh & Ravi Iyer. (2015) Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. Journal of Medical Economics 18:9, pages 711-720.
Read now
Read now
Gabriel Adelman, Stanley G. Rane & Kathleen F. Villa. (2013) The cost burden of multiple sclerosis in the United States: a systematic review of the literature. Journal of Medical Economics 16:5, pages 639-647.
Read now
Read now
J. I. Ivanova, R. E. Bergman, H. G. Birnbaum, A. L. Phillips, M. Stewart & D. M. Meletiche. (2012) Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Journal of Medical Economics 15:3, pages 601-609.
Read now
Read now
Articles from other publishers (16)
Barry Hendin, Richard Brook, Ian Beren, Nathan Kleinman, Cindy Fink, Amy Phillips & Carroline Lobo. (2023) The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity. Journal of Health Economics and Outcomes Research, pages 91-101.
Crossref
Crossref
Barry Hendin, Richard A. Brook, Ian A. Beren, Nathan Kleinman, Cindy Fink, Amy L. Phillips & Carroline Lobo. (2023) The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity. Journal of Health Economics and Outcomes Research 10:1.
Crossref
Crossref
Jas Bindra, Ishveen Chopra, Kyle Hayes, John Niewoehner, Mary Panaccio & George J. Wan. (2022) Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus. Advances in Therapy 40:1, pages 194-210.
Crossref
Crossref
Marcello Moccia, Giuseppina Affinito, Giulia Berera, Giuseppina Marrazzo, Raffaele Piscitelli, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra & Raffaele Palladino. (2022) Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy. Journal of Neurology 269:12, pages 6504-6511.
Crossref
Crossref
Bruce Bebo, Inna CintinaNicholas LaRoccaLeslie RitterBari TalenteDaniel HartungSurachat NgorsurachesMitchell Wallin & Grace Yang. (2022) The Economic Burden of Multiple Sclerosis in the United States. Neurology 98:18.
Crossref
Crossref
Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier & Neil Goldfarb. (2020) Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 5:1, pages 23-34.
Crossref
Crossref
Ivan Mauricio Muñoz-Galindo, Jairo Alexander Moreno Calderón, Natalia Elizabeth Guarín Téllez, Helbert Orlando Arévalo Roa & Jorge Augusto Díaz Rojas. (2018) Health Care Cost for Multiple Sclerosis: The Case of a Health Insurer in Colombia. Value in Health Regional Issues 17, pages 14-20.
Crossref
Crossref
M. Moccia, R. Palladino, R. Lanzillo, M. Triassi & V. Brescia Morra. (2017) Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurologica Scandinavica 135:5, pages 522-528.
Crossref
Crossref
Marcello Moccia, Raffaele Palladino, Roberta Lanzillo, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi & Vincenzo Brescia Morra. (2017) Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015. PLOS ONE 12:1, pages e0169489.
Crossref
Crossref
Mintu P. Turakhia, Jason Shafrin, Katalin Bognar, Dana P. Goldman, Philip M. Mendys, Younos Abdulsattar, Daniel Wiederkehr & Jeffrey Trocio. (2015) Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. The American Journal of Cardiology 116:5, pages 733-739.
Crossref
Crossref
Cathryn A Carroll, Kathleen A Fairman & Maureen J Lage. (2014) Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Services Research 14:1.
Crossref
Crossref
Sanober Nusrat, Elsie Gulick, David Levinthal & Klaus Bielefeldt. (2012) Anorectal Dysfunction in Multiple Sclerosis: A Systematic Review. ISRN Neurology 2012, pages 1-9.
Crossref
Crossref
Rachel Halpern, Sonalee Agarwal, Leigh Borton, Kathy Oneacre & Maria V. Lopez-Bresnahan. (2011) Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis. Advances in Therapy 28:9, pages 761-775.
Crossref
Crossref
Martin Romero, Carlos Arango, Nelson Alvis, Juan Camilo Suarez & Aristides Duque. (2011) Costos de la Esclerosis Múltiple en Colombia. Value in Health 14:5, pages S48-S50.
Crossref
Crossref
F. V. Bahinski, N. V. Galinovskaja, N. N. Usova, V. O. Demidova & V. Ja. Latysheva. (2010) MULTIPLE SCLEROSIS: MODERN VIEW ON THE PROBLEM (literature review). Health and Ecology Issues:3, pages 75-80.
Crossref
Crossref
Jasmina I. Ivanova, Howard G. Birnbaum, Seth Samuels, Matthew Davis, Amy L. Phillips & Dennis Meletiche. (2009) The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US. PharmacoEconomics 27:8, pages 681-691.
Crossref
Crossref